SpringerLink
Log in

Cognitive Adverse Effects of Antiepileptic Drugs

Incidence, Mechanisms and Therapeutic Implications

  • Adverse Effects
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Several early studies suggested that differences exist between antiepileptic drugs (AEDs) in terms of their propensity to cause adverse effects on cognitive functions, favouring carbamazepine over phenobarbital (phenobarbitone), phenytoin and valproic acid (sodium valproate). The combined results of recent studies in patients and healthy volunteers reveal that at therapeutic serum concentrations phenobarbital, phenytoin, carbamazepine, oxcarbazepine and valproic acid produce nearly comparable adverse effects on higher cognitive functions.

The newer AEDs (with the exception of zonisamide and topiramate) appear to induced fewer cognitive adverse effects than the older agents. Furthermore, there is limited evidence that gabapentin, lamotrigine and vigabatrin may have beneficial effects on cognitive function. Some of the newer AEDs may also have neuroprotective effects that can prevent seizure-induced neuronal damage, and so reduce cognitive dysfunction. This is an important clinical consideration, as even modest differences between older and newer AEDs are relevant for patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neisser U. Cognition and reality. San Francisco: W.H. Freeman and Co., 1980

    Google Scholar 

  2. Dodrill CB. Behavioral effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble M, editors. Neurobehavioral problems in epilepsy. Advances in neurology. Vol. 55. New York: Raven Press. 1991: 213–24

    CAS  Google Scholar 

  3. Sutula TP, Cavazos JE, Woodard AR. Long-term structural and functional alterations induced in the hippocampus by kindling: implications for memory dysfunction and the development of epilepsy. Hippocampus 1994: 4: 254–8

    Article  CAS  PubMed  Google Scholar 

  4. Äikiä M, Kälviäinen R, Riekkinen Sr PJ. Verbal learning and memory in newly diagnosed partial epilepsy. Epilepsy Res 1995 Oct: 22: 157–64

    Article  PubMed  Google Scholar 

  5. Brodie MJ, McPhail E, Macphee GJA, et al. Psychomotor impairment and anticonvulsant therapy in adult epileptic patients. Eur J Clin Pharmacol 1987: 31: 655–60

    Article  CAS  PubMed  Google Scholar 

  6. Kälviäinen R, Äikiä M, Helkala E-L, et al. Memory and attention in newly diagnosed epileptic seizure disorder. Seizure 1992: 1: 255–62

    Article  PubMed  Google Scholar 

  7. Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide veterans administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin and primidone. Epilepsia 1987: 28: 50–8

    Article  Google Scholar 

  8. Engel J, Bandler R, Gritfith NC, et al. Neurobiological evidence for epilepsy-induced interictal disturbances. In: Smith DB, Treiman DM, Trimble MR, editors. Neurobehavioral problems in epilepsy. New York: Raven Press. 1991: 97–111

    Google Scholar 

  9. Devinsky O. Cognitive and behavioral effects of antiepileptic. Epilepsia 1995: 36Suppl. 2: 46–65

    Article  Google Scholar 

  10. Dodrill CB. Cognitive and psychosocial effects of epilepsy on adults. In: Wyllie E. editor. The treatment of epilepsy: principles and practices. Philadelphia: Lea & Febiger. 1993: 1133–40

    Google Scholar 

  11. Loring DW, Meador KJ. Cognitive and behavioral effects of antiepileptic drugs: issues in epilepsy and quality of life. Epilepsy Foundation of America, 1993

    Google Scholar 

  12. Meador KJ, Loring DW. Cognitive effects of antiepileptic drugs. In: Devinsky O, Theodore WH. editors. Epilepsy and behavior. New York: Wiley-Liss, 1991: 151–70

    Google Scholar 

  13. Smith DB. Cognitive effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble M. editors. Neurobehavioral problems in epilepsy. Advances in neurology. Vol 55. New York: Raven Press. 1991: 197–212

    CAS  Google Scholar 

  14. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987: 28: 37–45

    Article  Google Scholar 

  15. Durwen HF, Eiger CE, Helmstaedter C, et al. Circumscribed improvement of cognitive performance in TLE patients with intractable seizures following reduction of anticonvulsant medication. J Epilepsy 1989: 2: 147–53

    Article  Google Scholar 

  16. Durwen HF, Eiger CE. Verbal differences in epileptic patients with left and right temporal lobe foci — a pharmacologically induced phenomenon? Acta Neurol Scand 1993: 87: 1–8

    Article  CAS  PubMed  Google Scholar 

  17. Gaily EK, Granström ML, Hiilesmaa VK, et al. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res 1990: 5: 217–22

    Article  CAS  PubMed  Google Scholar 

  18. Ransom BR, Elmore JG. Effects of antiepileptic drugs on the develo** central nervous system. In: Smith D, Treiman D, Trimble M, editors. Neurobehavioral problems in epilepsy. Advances in neurology. Vol. 55. New York: Raven Press, 1991: 225–37

    CAS  Google Scholar 

  19. Trimble MR, Reynolds EH. Anticonvulsant drugs and mental symptoms. Psychol Med 1976: 6: 169–78

    Article  CAS  PubMed  Google Scholar 

  20. Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. BMJ 1979: 2: 1023–5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Thompson P, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia 1982: 23: 531–44

    Article  CAS  PubMed  Google Scholar 

  22. Dodrill CB. Diphenylhydantoin serum levels, toxicity, and neuropsychological performance in patients with epilepsy. Epilepsia 1975: 16: 593–600

    Article  CAS  PubMed  Google Scholar 

  23. Thompson P, Trimble MR. Comparative effects of anticonvulsant drugs on cognitive functioning. Br J Clin Pract 1982: 18: 154–6

    Google Scholar 

  24. Thompson PJ, Trimble MR. Anticonvulsant serum levels: relationship to impairments of cognitive functioning. J Neurol Neurosurg Psychiatr 1983: 46: 227–33

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977: 27: 1023–8

    Article  CAS  PubMed  Google Scholar 

  26. Thompson PJ, Huppert FA, Trimble MR. Phenytoin and cognitive functions: effects on normal volunteers and implications for epilepsy. Br J Clin Psychol 1981: 20: 155–62

    Article  CAS  PubMed  Google Scholar 

  27. Thompson PJ, Trimble MR. Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol 1981: 12: 819–24

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Andrewes DG, Bullen JG, Tomlinson L, et al. A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 1986: 27: 128–34

    Article  CAS  PubMed  Google Scholar 

  29. Nichols ME, Meador KJ, Loring DW. Neuropsychological effects of antiepileptic drugs: a current perspective. J Clin Neuropharmacol 1993: 16: 471–84

    Article  CAS  Google Scholar 

  30. Smith DB. Anticonvulsants, seizures and performance: the Veteran’s Administration experience. In: Trimble MR, Reynolds EH, editors. Epilepsy, behaviour and cognitive function. Chichester: John Wiley & Sons Ltd, 1988: 67–78

    Google Scholar 

  31. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine and valproate on cognitive function. Epilepsia 1990; 31: 584–91

    Article  CAS  PubMed  Google Scholar 

  32. Gillham RA, Williams N, Wiedmann KD, et al. Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. Epilepsy Res 1990; 7: 219–25

    Article  CAS  PubMed  Google Scholar 

  33. Dodrill CB, Temkin NR. Motor speed is a contaminating factor in evaluating the cognitive effects of phenytoin. Epilepsia 1989; 30: 453–7

    Article  CAS  PubMed  Google Scholar 

  34. Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology 1991; 41: 141–3

    Article  CAS  PubMed  Google Scholar 

  35. Dodrill CB, Wilensky AJ. Neuropsychological abilities before and after 5 years of stable antiepileptic drug therapy. Epilepsia 1992; 33: 327–34

    Article  CAS  PubMed  Google Scholar 

  36. Prevey ML, Delaney RC, Cramer JA, et al. Valproate versus carbamazepine: comparison of effects on cognitive functioning [abstract]. Epilepsia 1992; 33Suppl. 3: 110

    Google Scholar 

  37. Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991; 33: 524–34

    Article  CAS  PubMed  Google Scholar 

  38. Dikmen SS, Temkin NR, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991; 265: 1271–7

    Article  CAS  PubMed  Google Scholar 

  39. Smith KR, Goulding PM, Wilderman D, et al. Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol 1994; 51: 653–60

    Article  PubMed  Google Scholar 

  40. Meador KJ, Loring DW, Huh K, et al. Comparative cognitive effects of anticonvulsants. Neurology 1990; 40: 391–4

    Article  CAS  PubMed  Google Scholar 

  41. Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991; 41: 1537–40

    Article  CAS  PubMed  Google Scholar 

  42. Meador KJ, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993; 34: 153–7

    Article  CAS  PubMed  Google Scholar 

  43. Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology 1995; 45: 1494–9

    Article  CAS  PubMed  Google Scholar 

  44. Kälviäinen R, Keränen T, Riekkinen Sr PJ. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993; 46: 1009–24

    Article  PubMed  Google Scholar 

  45. Kälviäinen R, Riekkinen PJ. New antiepileptic drugs. Exp Opin Invest Drugs 1995; 4: 955–62

    Article  Google Scholar 

  46. Chronopoulos A, Stafstrom C, Thurber S, et al. Neuroprotective effect of felbamate after kainic acid-induced status epilepticus. Epilepsia 1993; 43: 693–6

    Google Scholar 

  47. Wallis RA, Panizzon KL, Nolan JP. Glycine-induced CAI excitotoxicity in the rat hippocampal slice. Brain Res 1994; 664: 115–25

    Article  CAS  PubMed  Google Scholar 

  48. Wasterlcin CG, Adams LM, Hattori H, et al. Felbamate reduces hypoxic-ischemic brain damage in vivo. Eur J Pharmacol 1992; 212: 275–8

    Article  Google Scholar 

  49. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995; 36Suppl. 2: 13–26

    Article  Google Scholar 

  50. Ramsay RE. Clinical efficacy and safety of gabapentin. Neurology 1994; 44Suppl. 4: 23–30

    Google Scholar 

  51. Saletu B, Grunberger J, Linzmayer L. Evaluation of encephalothrophic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry. Int J Clin Pharmacol Ther Toxicol 1986; 24: 362–73

    CAS  PubMed  Google Scholar 

  52. Dodrill CB, Wilensky AJ, Ojemann LM. Neuropsychological, mood, and psychosocial effects of gabapentin [abstract]. Epilepsia 1992; 33Suppl. 3: 117–8

    Google Scholar 

  53. Abou-Khalil B, McLean M, Castro O, et al. Gabapentin in the treatment of refractory partial seizures [abstract]. Epilepsia 1990; 31: 644

    Google Scholar 

  54. Handforth A, Treiman DM, Norton LC. Effect of gabapentin on complex partial seizure frequency [abstract]. Neurology 1989; 39Suppl. 1: 114

    Google Scholar 

  55. Ojemann LM, Wilensky AJ, Temkin NR, et al. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992; 13: 159–65

    Article  CAS  PubMed  Google Scholar 

  56. Arnett JL, Dodrill CB. Effects of gabapentin on cognitive functioning and mood [abstract]. Epilepsia 1995; 36Suppl. 3: 32

    Google Scholar 

  57. O’Donnell RA, Miller AA. The effect of lamotrigine upon development of cortical kindled seizures in the rat. Neuropharmacology 1991; 30: 253–8

    Article  PubMed  Google Scholar 

  58. McGeer EG, Zhu SG. Lamotrigine protects against kainate but not ibonate lesions in rat striatum. Neurosci Lett 1990; 4: 348–51

    Article  Google Scholar 

  59. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117–22

    Article  CAS  PubMed  Google Scholar 

  60. Cohen AF, Ashby L, Crowley D, et al. Lamotrigine (BW 43OC), potential anticonvulsant: effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985; 20: 619–29

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Hamilton MJ, Cohen AF, Yuen AWC, et al. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 1993; 34: 166–73

    Article  CAS  PubMed  Google Scholar 

  62. Mervaala E, Koivisto K, Hänninen T, et al. Electrophysiological and neuropsychological profiles of lamotrigine in young and age-associated memory impairment subjects [abstract]. Neurology 1995; 46Suppl. 4: 259

    Google Scholar 

  63. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34: 312–22

    Article  CAS  PubMed  Google Scholar 

  64. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691–713

    Article  CAS  PubMed  Google Scholar 

  65. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 25: 476–9

    Article  Google Scholar 

  66. Steiner TJ, Silveira C, Yuen AWC. Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy [abstract]. Epilepsia 1994; 35: 61

    Article  Google Scholar 

  67. Grant S, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873–88

    Article  CAS  PubMed  Google Scholar 

  68. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol 1991; 29: 356–63

    Article  CAS  PubMed  Google Scholar 

  69. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529–33

    Article  CAS  PubMed  Google Scholar 

  70. Laaksonen R, Kaimola K, Grahn-Teräväinen E, et al. A controlled trial of the effects of carbamazepine and oxcarbazepine on memory and attention [abstracl]. 16th International Epilepsy Congress; 1985; Hamburg.

  71. Sabers A. The effect of carbamazepine, sodium-valproate and oxcarbazepine on neuropsychological functions in patients with epilepsy [abstract]. Acta Neurol Scand 1990; 82: 80

    Google Scholar 

  72. Äikiä M, Kälviäinen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992; 11: 199–203

    Article  PubMed  Google Scholar 

  73. Rogawski MA. The NMDA receptor, NMDA antagonists and epilepsy therapy: a status report. Drugs 1992; 44: 279–92

    Article  CAS  PubMed  Google Scholar 

  74. Bannan PE, Graham DI, Lees KR, et al. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res 1994; 664: 271–5

    Article  CAS  PubMed  Google Scholar 

  75. Ordy JM, Thomas GJ. Remacemide effects on memory and hippocampal CA1 neuronal damage in the rat four-vessel occlusion model of global cerebral ischemia [abstract]. Soc Neurosci Abstr 1991; 17: 1081

    Google Scholar 

  76. Jamieson V. Preclinical and early clinical experience: remacemide hydrochloride safety — anticonvulsant and neuroprotectant? Satellite symposium in 21 st International Epilepsy Congress; 1995 Sept 4-8; Sydney

  77. Halonen T, Nissinen J, Jansen J, et al. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur J Pharmacol. In press

  78. Sveinbjornsdottir S, Sander JWAS, Patsalos PN, et al. Neuropsychological effects of tiagabine. a potential new antiepileptic drug. Seizure 1994; 3: 29–35

    Article  CAS  PubMed  Google Scholar 

  79. Dodrill C, Arnett JL, Sommerville K, et al. Tiagabine [abstract]. Epilepsia 1995; 36Suppl. 3: 31

    Google Scholar 

  80. Kälviäinen R, Äikiä M, Mervaala E, et al. Long-term cognitive effects of tiagabine [abstract]. Epilepsia 1995; 36Suppl. 3: 149

    Google Scholar 

  81. Privitera M. Long-term cognitive effects of topiramate [abstract]. Epilepsia 1995; 36Suppl. 3: 152

    Google Scholar 

  82. Brooks J, Sachdeo R, Lim P. Topiramate: neuropsychometric assessments [abstract]. Epilepsia 1995; 36Suppl. 3: 273

    Google Scholar 

  83. Shin C, Rigsbee LC, McNamara JO. Anti-seizure and anti-epileptogenic effect of gamma-vinyl-gamma-aminobutyric acid in amygdaloid kindling. Brain Res 1986; 398: 370–4

    Article  CAS  PubMed  Google Scholar 

  84. Ylinen AMA, Miettinen R, Pitkänen A, et al. Enhanced GABA-ergic inhibition preserves hippocampal structure and function in a model of epilepsy. Proc Natl Acad Sci USA 1991; 88: 7650–3

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  85. Pitkänen A, Tuunanen J, Halonen T. Vigabatrin and carbamazepine have different efficacies in prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala. Epilepsy Res. In press

  86. Dodrill CB, Arnett JL, Sommerville KW, et al. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993; 43: 2501–7

    Article  CAS  PubMed  Google Scholar 

  87. Dodrill CB, Arnett JL, Sommerville KW, et al. Effects of differing dosages of vigabatrin on cognitive abilities and quality of life in epilepsy. Epilepsia 1995; 36: 164–73

    Article  CAS  PubMed  Google Scholar 

  88. Gillham RA, Blacklaw J, McKee PJW, et al. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 1993; 53: 1271–5

    Article  Google Scholar 

  89. Grunewald RA, Thompson PJ, Corcoran R, et al. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry 1994; 57: 1057–63

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  90. McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992; 33: 128–34

    Article  CAS  PubMed  Google Scholar 

  91. Kälviäinen R, Äikiä M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arch Neurol 1995; 52: 989–96

    Article  PubMed  Google Scholar 

  92. Kälviäinen R, Äikiä M, Riekkinen PJ. Vigabatrin monotherapy in newly diagnosed patients with epilepsy: two-year comparative follow-up of efficacy, safety and cognitive effects [abstract]. Epilepsia 1995; 36Suppl. 3: 105

    Google Scholar 

  93. Hamoda K, Ishida S, Yagi K. Anticonvulsant effects of zonisamide on amygdaloid kindling in rats. Neuroscience 1990; 16: 407–12

    Google Scholar 

  94. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy. Drugs 1993; 45: 760–87

    Article  CAS  PubMed  Google Scholar 

  95. Berent S, Sackellares JC, Giordani B, et al. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987; 28: 61–7

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital of Kuopio, POB 1777, 70211, Kuopio, Finland

    Reetta Kälviäinen & Marja Äikiä

  2. A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland

    Paavo J. Riekkinen Sr

Authors
  1. Reetta Kälviäinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marja Äikiä
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paavo J. Riekkinen Sr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kälviäinen, R., Äikiä, M. & Riekkinen, P.J. Cognitive Adverse Effects of Antiepileptic Drugs. CNS Drugs 5, 358–368 (1996). https://doi.org/10.2165/00023210-199605050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199605050-00005

Keywords

Search

Navigation